Glenmark’s Melogliptin has recently completed 12 weeks phase-IIb clinical trial in 494 patients with type 2 diabetes mellitus, and is now ready to initiate phase III trials.
In the 12-week, randomized, double-blind, placebo-controlled, parallel group study, Melogliptin reportedly showed good possibilities. It significantly reduced HbA1c from baseline, as compared to placebo, with a mean average reduction of 0.75% in patients receiving 50mg twice daily dose and 0.60 % in patients receiving 100mg once daily dose .
Glenn Saldanha, MD and CEO of Glenmark, said: “Global Phase III trials have been planned with Melogliptin and are due to start at the end of 2009 following regulatory approvals. These studies are designed to evaluate the compound both as monotherapy and in combination with other anti-diabetic therapies in patients with type 2 diabetes mellitus.”